Jaromír R.
- Country
- Czechia
- Department
- Plicni oddeleni
Research Overview
- Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 357 of 613 partner sites.
Specializations
Non-Small Cell Lung Cancer
The clinical research focus centers on non-small cell lung cancer across locally advanced, metastatic, and resected settings, with attention to molecularly defined subgroups and treatment-resistant disease. The portfolio includes studies in EGFR-mutated, ALK-positive, RET fusion-positive, KRAS G12C-mutant, and HER2-altered disease, as well as PD-L1-selected populations.
- Metastatic NSCLC
- EGFR-mutated lung cancer
- ALK-positive NSCLC
- KRAS G12C-mutant disease
- RET fusion-positive NSCLC
Therapeutic interests extend to targeted treatment strategies, immunotherapy-based combinations, and adjuvant approaches in surgically treated disease.
Small Cell Lung Cancer
Another major area of activity is small cell lung cancer, including both extensive-stage and limited-stage disease. The trial landscape reflects interest in disease control after prior therapy and in first-line treatment settings.
- Extensive-stage SCLC
- Limited-stage SCLC
- Relapsed SCLC
- First-line SCLC treatment
The therapeutic domain includes immunotherapy, antibody-based treatments, and combination regimens for aggressive thoracic malignancies.
Ischemic Stroke
The investigator is also involved in studies of acute ischemic stroke and secondary prevention after transient ischemic attack. This area includes patients with recent non-cardioembolic cerebrovascular events and those at elevated risk of recurrence.
- Acute ischemic stroke
- High-risk transient ischemic attack
- Stroke prevention
- Post-stroke vascular risk reduction
Therapeutic interest is directed toward antithrombotic and neurovascular strategies aimed at reducing recurrent cerebral ischemia.
Obesity and Weight Management
Clinical research activity also includes obesity and overweight in adolescents with associated weight-related comorbidities. This expands the investigator's portfolio beyond oncology and vascular medicine into metabolic care.
- Adolescent obesity
- Overweight with comorbidities
- Metabolic risk reduction
The therapeutic emphasis is on interventions addressing excess body weight and related cardiometabolic burden.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.